Objectives: This study evaluated the use of a paclitaxel-eluting balloon (PEB) for treatment of
femoropopliteal arterial disease. Background: Conventional balloon angioplasty and …

Objectives: This study aimed to appraise 2-year outcomes after percutaneous treatment of
femoropopliteal artery disease with paclitaxel-eluting balloons. Background: Percutaneous …

Objectives This study evaluated the 12-month safety and effectiveness of a paclitaxel drug-
coated balloon for treatment of intermittent claudication or rest pain in subjects with …

Objectives: The aim of this study was to appraise 2-year outcomes after percutaneous
transluminal angioplasty of long femoropopliteal artery disease using paclitaxel-coated …

Objectives: The aim of this study was to appraise 1-year outcomes after percutaneous
treatment of long femoropopliteal artery disease using paclitaxel-coated balloons …

Objectives To assess the safety and effectiveness of the Stellarex™ drug‐coated
angioplasty balloon (DCB) to inhibit restenosis in the superficial femoral and/or popliteal …

Aims To evaluate safety and results of the Freepac drug-eluting balloon (DEB) technology
for the treatment of chronic femoropopliteal steno-occlusions. Methods and results In a …

Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …

Objectives: The authors sought to investigate the midterm efficacy and safety of drug-coated
balloon (DCB) in the treatment of severe femoropopliteal artery disease (FPAD) …